Coming off semaglutide or tirzepatide: how a protocol handles the transition

First: this is a physician conversation

Semaglutide and tirzepatide are prescription medicines. Coming off one, for any reason, is a decision you make with the doctor who prescribed it — not with a coach, and not with a document. What a personal research protocol does is give that conversation a plan to look at: a written schedule for the taper, the phase-in and the labs, in a physician copy your prescriber can read in ten minutes. The retatrutide and tirzepatide pages explain the compounds; this guide explains the handover between them.

Why people switch at all

• The weight loss has stalled at the current dose and the next step is not available or not wanted.
• Side effects — nausea, reflux, constipation — have not settled after months.
• The goal has changed from "lose weight" to "lose fat and keep muscle", and the plan around the compound has to change with it: protein, resistance training, the labs that show lean mass is holding.
• Interest in retatrutide specifically, whose triple-agonist action shows a stronger fat-loss signal in research settings than the dual-agonist tirzepatide or the single-agonist semaglutide.

None of these is a reason to stop a prescribed medicine on your own. All of them are reasons to bring a written plan to the person who prescribed it.

The house transition rule

Every protocol that involves a switch from a GLP-1 medicine to retatrutide follows the same shape. It is written into the full clinical document week by week, and it has three parts.

The starting dose is the house starting dose — 1.5 mg a week for women, 2 mg for men (19 and 25 clicks on the 24 mg pen; the pen-clicks guide shows the arithmetic). It is not raised because you were on a high dose of the old medicine, and it is not lowered below the house start unless you are known to be GI-sensitive. Tolerance to semaglutide does not transfer cleanly to a compound that also acts on the glucagon receptor, and the ramp exists to find out how you respond, not to assume it.

Why no overlap at full dose

Semaglutide and tirzepatide have long half-lives — roughly a week — which means a dose taken on Sunday is still substantially present the following Sunday. Stop one and start the other at full dose on the same day and for two or three weeks you are effectively running both. Three things go wrong:

1. Side effects stack. Nausea, slowed stomach emptying and constipation from two compounds at once are the commonest reason a switch is abandoned in week 2.
2. Appetite collapses. Two full doses can push intake so low that protein falls below what muscle needs, which is the opposite of the goal that prompted the switch.
3. Nothing can be read. If week 2 is bad, nobody can say which compound is responsible. The taper-then-phase-in shape keeps the signal clean for the week-2 check-in.

The taper is therefore not caution for its own sake. It is what makes the first three weeks interpretable, and it is the part your prescriber is most likely to want to shape.

Appetite, hydration and protein in the switch weeks

Appetite

Expect it to be unpredictable for about three weeks: lower than usual in week 1 as the two compounds overlap at reduced doses, sometimes returning briefly in week 3 as the old one clears, then settling as retatrutide reaches its hold dose. The protocol writes a minimum — not a maximum — for food in these weeks. Skipping meals because you can is the wrong lesson from the switch.

Hydration

Both the old and the new compound slow the stomach and blunt thirst at the same time. The house rule on the retatrutide page applies from day one: a fixed daily water target with electrolytes, written as a number in your document, and tracked in the log. Headaches and dizziness in the first two weeks are more often hydration than dose.

Protein and training

The switch is the moment to fix the thing most GLP-1 plans get wrong: muscle. The protocol sets a daily protein target in grams per kilogram of goal body weight, three full-body resistance sessions a week at the weights you were lifting before, and 8–10 thousand steps. No new endurance programme during the switch weeks, and training on a small meal rather than fasted. The fat-loss page explains why falling lifts, not the scale, are the early warning.

Labs around the switch

Baseline before week 1, as for any cycle — HbA1c, fasting glucose and insulin, lipids with ApoB, liver enzymes, cystatin C, a full blood count, TSH; the baseline-labs guide has the full list. If you are also on insulin, a sulfonylurea or any other glucose-lowering medication, the hypoglycaemia risk during the overlap is a prescriber decision and the protocol says so on its first page. The week-6 repeat is unchanged. Anyone with a history of pancreatitis, medullary thyroid carcinoma or MEN2, pregnancy or breastfeeding, under 18, or with a BMI under 22 does not get a switch protocol written at all.

What the three documents contain for a switch

• The results version: the three-week shape in plain words, the food minimum, the water number, the check-in dates and the symptoms that mean "stop and call your doctor".
• The full clinical protocol: the taper schedule to agree with your prescriber, the retatrutide ramp in milligrams and clicks from week 1, the hold rule, the split-dose option for nausea, the labs.
• The physician copy: both compounds by name and class, the overlap rationale, the interactions considered, the glucose-lowering caution, and what we are asking your prescriber to decide.

How a dose is physically taken — technique, site, equipment — is a conversation for your coach and your physician, not a document. Read next: what a 12-week cycle looks like for weeks 4 to 12.